AFJKR
AFJKR
Aimei Health Technology Co., LtdIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▼ |
| Q1-2025 | $0 | $413.41K ▲ | $184.66K ▼ | 0% | $0.02 ▼ | $184.66K ▼ |
| Q4-2024 | $0 | $402.02K ▲ | $444.11K ▼ | 0% | $0.05 ▼ | $444.11K ▼ |
| Q3-2024 | $0 | $200.02K | $743.51K | 0% | $0.08 | $743.51K |
What's going well?
The company is earning strong interest income ($482,171), which more than covers its operating losses. Lower share count helps boost earnings per share.
What's concerning?
There is no revenue, operating losses are getting worse, and the only profit comes from interest income. This is not a sustainable business model if interest income drops.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K ▼ | $43.6M ▼ | $2.38M ▲ | $41.23M ▼ |
| Q4-2024 | $28.21K ▼ | $73.81M ▲ | $1.51M ▲ | $72.31M ▲ |
| Q3-2024 | $103.56K | $72.78M | $920.79K | $71.86M |
What's financially strong about this company?
The company has a large equity cushion and almost all its assets are in long-term investments, with no goodwill or intangible risk. Debt is small compared to total assets.
What are the financial risks or weaknesses?
Cash is dangerously low, and all debt is due soon. The company can't cover its bills with current assets, and negative retained earnings show a history of losses.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K ▼ | $-224.01K ▼ | $30.79M ▲ | $-30.58M ▼ | $-20.86K ▲ | $-224.01K ▼ |
| Q4-2024 | $444.11K ▼ | $-195.13K ▼ | $-277.7K ▼ | $397.48K ▲ | $-75.35K ▼ | $-195.13K ▼ |
| Q3-2024 | $743.51K | $-53.95K | $0 | $0 | $-53.95K | $-53.95K |
What's strong about this company's cash flow?
Cash burn is getting smaller each quarter, and working capital helped cash flow this time. If this trend continues, the company could eventually reach break-even.
What are the cash flow concerns?
The company is not generating cash from its business and must borrow every quarter just to keep going. Cash on hand is very low, and there's no sign of self-sufficiency yet.
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
AFJKR has a sizable asset base and relatively low structural leverage, giving it a solid long‑term capital foundation if the merger proceeds. Its recent accounting profitability, though driven by interest income, shows that the financial assets can generate meaningful returns in the interim. Strategically, the planned merger with United Hydrogen would transform the company from a cash shell into a participant in a high‑growth, policy‑supported sector. United Hydrogen brings an integrated hydrogen ecosystem, strong claimed positioning in China, deep municipal relationships, flexible commercial models, and a clear focus on innovation and technology‑enabled services, all of which can support a differentiated market stance.
The most immediate risk is liquidity: cash has fallen sharply while short‑term liabilities and short‑term debt have risen, and operating and free cash flows are negative. AFJKR has no operating revenue today, so it relies on its investment balances and external financing to cover costs until the transaction closes. There is also structural risk that the merger with United Hydrogen could be delayed, altered, or not completed, which would leave a cash‑constrained SPAC needing to find alternatives. Longer term, the hydrogen business faces significant uncertainties—heavy capital requirements, fast‑moving technology, intense competition, and dependence on government policy and subsidies. Operating primarily in China through an offshore structure and U.S. listing also introduces regulatory, governance, and geopolitical risks, and the success of the strategy relies heavily on execution of complex projects like city‑level ecosystems and large‑scale plants.
In the near term, AFJKR’s outlook is dominated by transaction and liquidity dynamics rather than by operating performance. The key variables are the successful completion of the United Hydrogen merger, the timing of that process, and the company’s ability to manage cash outflows until then. If the combination is completed as envisioned, the outlook shifts to the growth prospects of the hydrogen sector and United Hydrogen’s ability to turn its integrated ecosystem and innovation pipeline into sustainable revenue, profits, and cash flows. There is meaningful upside potential if hydrogen adoption in China and globally accelerates and the company executes well, but outcomes are highly uncertain and could vary widely depending on policy support, capital access, and operational delivery.
About Aimei Health Technology Co., Ltd
Aimei Health Technology Co., Ltd does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. It intends to acquires businesses in the biopharmaceutical, medical technology/device industries or diagnostic, and other services sectors.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▼ |
| Q1-2025 | $0 | $413.41K ▲ | $184.66K ▼ | 0% | $0.02 ▼ | $184.66K ▼ |
| Q4-2024 | $0 | $402.02K ▲ | $444.11K ▼ | 0% | $0.05 ▼ | $444.11K ▼ |
| Q3-2024 | $0 | $200.02K | $743.51K | 0% | $0.08 | $743.51K |
What's going well?
The company is earning strong interest income ($482,171), which more than covers its operating losses. Lower share count helps boost earnings per share.
What's concerning?
There is no revenue, operating losses are getting worse, and the only profit comes from interest income. This is not a sustainable business model if interest income drops.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K ▼ | $43.6M ▼ | $2.38M ▲ | $41.23M ▼ |
| Q4-2024 | $28.21K ▼ | $73.81M ▲ | $1.51M ▲ | $72.31M ▲ |
| Q3-2024 | $103.56K | $72.78M | $920.79K | $71.86M |
What's financially strong about this company?
The company has a large equity cushion and almost all its assets are in long-term investments, with no goodwill or intangible risk. Debt is small compared to total assets.
What are the financial risks or weaknesses?
Cash is dangerously low, and all debt is due soon. The company can't cover its bills with current assets, and negative retained earnings show a history of losses.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K ▼ | $-224.01K ▼ | $30.79M ▲ | $-30.58M ▼ | $-20.86K ▲ | $-224.01K ▼ |
| Q4-2024 | $444.11K ▼ | $-195.13K ▼ | $-277.7K ▼ | $397.48K ▲ | $-75.35K ▼ | $-195.13K ▼ |
| Q3-2024 | $743.51K | $-53.95K | $0 | $0 | $-53.95K | $-53.95K |
What's strong about this company's cash flow?
Cash burn is getting smaller each quarter, and working capital helped cash flow this time. If this trend continues, the company could eventually reach break-even.
What are the cash flow concerns?
The company is not generating cash from its business and must borrow every quarter just to keep going. Cash on hand is very low, and there's no sign of self-sufficiency yet.
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd's financial evolution and strategic trajectory over the past five years.
AFJKR has a sizable asset base and relatively low structural leverage, giving it a solid long‑term capital foundation if the merger proceeds. Its recent accounting profitability, though driven by interest income, shows that the financial assets can generate meaningful returns in the interim. Strategically, the planned merger with United Hydrogen would transform the company from a cash shell into a participant in a high‑growth, policy‑supported sector. United Hydrogen brings an integrated hydrogen ecosystem, strong claimed positioning in China, deep municipal relationships, flexible commercial models, and a clear focus on innovation and technology‑enabled services, all of which can support a differentiated market stance.
The most immediate risk is liquidity: cash has fallen sharply while short‑term liabilities and short‑term debt have risen, and operating and free cash flows are negative. AFJKR has no operating revenue today, so it relies on its investment balances and external financing to cover costs until the transaction closes. There is also structural risk that the merger with United Hydrogen could be delayed, altered, or not completed, which would leave a cash‑constrained SPAC needing to find alternatives. Longer term, the hydrogen business faces significant uncertainties—heavy capital requirements, fast‑moving technology, intense competition, and dependence on government policy and subsidies. Operating primarily in China through an offshore structure and U.S. listing also introduces regulatory, governance, and geopolitical risks, and the success of the strategy relies heavily on execution of complex projects like city‑level ecosystems and large‑scale plants.
In the near term, AFJKR’s outlook is dominated by transaction and liquidity dynamics rather than by operating performance. The key variables are the successful completion of the United Hydrogen merger, the timing of that process, and the company’s ability to manage cash outflows until then. If the combination is completed as envisioned, the outlook shifts to the growth prospects of the hydrogen sector and United Hydrogen’s ability to turn its integrated ecosystem and innovation pipeline into sustainable revenue, profits, and cash flows. There is meaningful upside potential if hydrogen adoption in China and globally accelerates and the company executes well, but outcomes are highly uncertain and could vary widely depending on policy support, capital access, and operational delivery.

CEO
Junheng Xie
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+

